|Home||Log In||Register||Our Services||My Account||Contact||Help|
|Stockwatch||Level 2||Portfolio||Charts||Share Price||Awards||Market Scan||Videos||Broker Notes||Director Deals||Traders' Room|
|Funds||Trades||Terminal||Alerts||Heatmaps||News||Indices||Forward Diary||Forex Prices||Shares Magazine||Investors' Room|
|CFDs||Shares||SIPPs||ISAs||Forex||ETFs||Comparison Tables||Spread Betting|
All attendees will be entered into free prize draws for:
Two pairs of tickets for Sale Sharks v Wasps on Sat 7th April at the AJ Bell Stadium, Eccles, Manchester M30 7WH http://www.salesharks.com
Champagne afternoon tea for TWO at Cloud 23 on the 23rd floor of the legendary Beetham Tower in Deansgate, Manchester. https://www.cloud23bar.com/
Evening Tasting Gift Experience at the Manchester Wine School. A gift voucher for TWO places on one of their evening tastings in Manchester City Centre. Gin, Champagne & Sparkling, Cheese or Food and Wine tasting/special event course of your choice. http://www.manchesterwineschool.com
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Tuesday 20 February 2018Venue:
Macdonald Manchester Hotel, London Road, Manchester, M1 2PGEvent Timings:
Registration and coffee
• Andrew Newland, Chief Executive - ANGLE
• Kiran Morzaria, Director & CEO - Cadence Minerals (KDNC)
• Brian Stockbridge, CEO - First Sentinel
• Charles Tatnall, Executive Chairman - Plutus PowerGen
• Dave Mutton, COO - PrimaryBid
• Cath O'Neill, CEO - SkinBioTherapeutics
Drinks reception and canapés
AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Lifetime ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £1.50 and never costs more than £9.95 per online deal.
PrimaryBid is a leading FinTech business enabling investors to gain access to fundraisings of companies listed on UK Stock Exchanges. Our unique solution connects the large and active pool of private investors, with companies seeking to raise capital by issuing new shares.
Traditionally, fundraises for listed companies have only been accessible by Institutions and a small number of high net worth investors, PrimaryBid allows all investors to have access to these fundraises at the same time and the same price, delivering open access regardless of the size of their investment. To date over £52m has been sourced via the platform.
ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L).
ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.
The primary application is the capture of circulating tumour cells (CTCs) in patient blood for:
· Early detection of cancer;
· Personalised cancer treatment;
· Monitoring of cancer patients during treatment; and
· Post-treatment monitoring of cancer patients in remission.
Cadence is dedicated to smart investments for a greener world. The planet needs rechargeable batteries on a global scale – upcoming supersized passenger vehicles, lorries and buses – require lithium and other technology minerals to power their cells. Cadence is helping find these minerals in new places and extracting them in new ways, which will meet the demand of this burgeoning market. With over £35 million vested in key assets globally, Cadence is helping us reach tomorrow, today.
First Sentinel is a consortium of companies focused on alternative investments, specializing in equity and debt deals with appealing IRRs, as well as traditional Corporate Finance and Legal Services.
This consortium enables us to support our clients end to end, whether it be the individual investor or corporate offering.
First Sentinel PLC (NEX: FSEN) is an alternative investment company that provides growth capital for public and private company investments. (NEX: FSEN).
Plutus PowerGen is a profitable AIM listed company that is constructing flexible generation and gas powered projects in the UK. It has identified multiple revenue streams and each site is relatively low cost to deliver.
Plutus PowerGen has six operating projects across the UK with a further 400MW of sites under development. Since the introduction of intermittent, renewable power to the UK’s power generation mix, the National Grid is facing increasing instability and risk of brownouts and blackouts. Therefore a reliable source of power is required during periods of peak electricity demand and Plutus PowerGen’s projects can be turned on rapidly and remotely to address this requirement. Importantly, the Company has received an offer from a leading ‘Big Six’ multinational utility company to fund up to 20% of any 20MW renewable fuel or gas powered flexible energy projects going forward.
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.